Eva Harth, Ph.D.
Associate Professor of Chemistry
7619 Stevenson Center
Nashville, TN 37235-1822
Eva Harth studied chemistry at the University of Bonn, Germany, and the University of Zurich, Switzerland. In 1998 she obtained her Ph.D. for work in the area of fullerene adducts and polymers from the MPI for
Eva Harth studied chemistry at the University of Bonn, Germany, and the University of Zurich, Switzerland. In 1998 she obtained her Ph.D. for work in the area of fullerene adducts and polymers from the MPI forPolymer Research. A postdoctoral fellowship with CPIMA (NSF-Center for Polymer Interfaces and Macromolecular Assemblies) brought her to the IBM Almaden Research Center, California USA, to work under the direction of Prof. Craig J. Hawker. In 2001 she joined XenoPort, Inc. as a Staff Scientist investigating enabling technologies for the increased bioavailability of macromolecular therapeutics and took a position as Assistant Professor at Vanderbilt University in the Department of Chemistry in 2004 with a secondary appointment in the department of Pharmacology. In 2011 she was promoted to Associate Professor with tenure and is member of the VINSE and VICB. She is serving on the Editorial Board of Polymer Chemistry, RSC, since its start in 2009 and is one of the Associate Editors. The focus of her research advances delivery technologies across challenging biological barriers and towards the treatment of cancer.
- Ph.D., Max Planck Institute for Polymer Research, Mainz, Germany, 1998
- M.S. University of Zurich, Switzerland, 1994
development of bioinspired nanoscopic polymeric materials establishing and implementing new achievements in targeted drug delivery and imaging
The discrepancy between the progress in the development of highly potent drugs and the ability to administer these moieties selectively to reach their targets has given bio-nanotechnologies the highest prospective for future breakthroughs. We develop functionalized nanoobjects from suitable precursors, with the goal to provide versatile platforms for innovative vectors for therapeutics and imaging reagents in nanomedicine. The versatility of these systems is facilited by their functionality, nature of polymeric backbones and bioconjugation strategies. Polymeric architectures we are working with include bioinspired nanosponges in the 5-10nm range, starpolymers and degradable systems.